文献速递甲状腺与颈部外科围术期管理与 ERAS

甲状腺癌术后能量水平与疲劳:基于人群的患者报告结局研究

Energy level and fatigue after surgery for thyroid cancer: A population-based study of patient-reported outcomes.
PubMed 文献 · Surgery · 2019-09-30

本研究纳入2014至2015年SEER登记中佐治亚州和加州洛杉矶的2584例分化型甲状腺癌患者,诊断后2至4年调查。结果显示38.2%报告能量较治疗前变差,50.7%报告中度至重度疲劳;甲状腺激素抑制治疗和放射性碘治疗与能量变差相关,术后低钙也相关。

要点

  • 分化型甲状腺癌术后2至4年,38.2%患者能量较术前变差,50.7%有中度至重度疲劳。
  • 甲状腺激素抑制治疗与能量变差和显著疲劳均相关(OR分别为1.48和1.63)。
  • 放射性碘治疗与能量变差相关(OR 1.31),术后低钙>3个月与能量变差及疲劳相关。

核心结论

  • 除抑郁和合并症外,放射性碘治疗和术后低钙与分化型甲状腺癌患者能量较术前变差相关,甲状腺激素抑制治疗与能量变差和显著疲劳均相关。

研究设计与样本

  • 基于SEER登记的人群研究,纳入2014至2015年佐治亚州和加州洛杉矶登记的分化型甲状腺癌患者,诊断后2至4年调查,共2584例 respondent。

主要发现

  • 988例(38.2%)报告能量较治疗前差很多或有些差,1310例(50.7%)报告中度至非常严重疲劳。
  • 多数患者接受全甲状腺切除伴或不伴淋巴结清扫(全切+淋巴结清扫49.3%,全切38.3%),仅12.3%行甲状腺腺叶切除。
  • 56.7%接受放射性碘治疗,50.2%术后接受甲状腺激素抑制治疗。
  • 能量变差的相关因素包括较年轻年龄、抑郁史、甲状腺激素抑制(OR 1.48,95%CI 1.21-1.82)、放射性碘治疗(OR 1.31,95%CI 1.10-1.56)。
  • 显著疲劳的相关因素包括较年轻年龄、更多合并症、抑郁史、甲状腺激素抑制(OR 1.63,95%CI 1.34-1.99),术后低钙>3个月与能量变差(OR 1.26,95%CI 1.02-1.54)和显著疲劳(OR 1.49,95%CI 1.21-1.84)相关。

临床怎么用

  • 对分化型甲状腺癌术后患者应关注能量下降和疲劳,尤其接受甲状腺激素抑制治疗、放射性碘治疗或术后低钙持续>3个月者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: The relationship between treatment for differentiated thyroid cancer and patient-report of decreased energy and fatigue remains unclear. METHODS: Patients diagnosed with differentiated thyroid cancer from 2014 to 2015 included in the Georgia and Los Angeles, California cancer registries of the Surveillance, Epidemiology, and End Results program were surveyed 2 to 4 years after diagnosis, and responses were linked to data from the Surveillance, Epidemiology, and End Results registry. Multivariable logistic regression analysis determined characteristics associated with the report of worse energy level at 2 to 4 years compared to before treatment and current fatigue severity using adjusted odds ratios with 95% confidence intervals. RESULTS: Of the 2,584 respondents, 988 (38.2%) reported much worse or somewhat worse energy and 1,310 (50.7%) reported moderate to very severe fatigue. The majority of patients were treated with total thyroidectomy with or without nodal dissection (total thyroidectomy with lymph node removal [49.3%] or total thyroidectomy [38.3%]). Only 12.3% had a thyroid lobectomy. Just over half were treated with radioactive iodine therapy (56.7%) and thyroid hormone suppression (50.2%) after the thyroidectomy. Younger age, history of depression, thyroid hormone suppression (odds ratio 1.48 [confidence interval 1.21-1.82]), and receipt of radioiodine (odds ratio 1.31 [confidence interval 1.10-1.56]) correlated with worse energy. Similarly, correlates of substantial fatigue included younger age, more comorbidities, history of depression, and thyroid hormone suppression (odds ratio 1.63 [confidence interval 1.34-1.99]). The presence of low serum calcium levels for >3 months after thyroidectomy was associated with worse energy (odds ratio 1.26 [confidence interval 1.02-1.54]) and substantial fatigue (odds ratio 1.49 [confidence interval 1.21-1.84]). CONCLUSION: In addition to accepted risk factors such as depression and comorbidities, receiving radioactive iodine and reporting low calcium after thyroidectomy for differentiated thyroid cancer were associated with reports of worse energy compared to preoperative levels; thyroid hormone suppression was associated with reports of both worse energy and substantial post-treatment fatigue.

来源:Surgery,查看原文。版权归原作者所有。

引用

  1. Hughes DT, Reyes-Gastelum D, Kovatch KJ, et al. Energy level and fatigue after surgery for thyroid cancer: A population-based study of patient-reported outcomes. Surgery. 2019. PMID: 31582311. doi:10.1016/j.surg.2019.04.068

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。